AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, is a recognized innovator and leader in the field of early cancer screening and detection. Its core product and proven revenue generator, the pioneering Cancer Differentiation Analysis (“CDA”) platform, offers novel capabilities by looking for signals to help it assess the risk of cancer occurring before a tumor has developed. This approach is unlike the blood sample-based cancer screenings, which generally target protein-based biomarkers, genomic signals, such as circulating tumor DNA (“ct-DNA”), circulating in the bloodstream to determine if a cancer exists and is spreading. “In addition to CDA technology’s ability to detect early cancer risk, this technology has unique advantages in detecting multiple cancer types and is highly cost effective,” reads a recent article. “In 2015, the company performed its first commercial CDA-based test, with the capacity to screen for 16 different types of cancer using a multi-level, multi-parameter approach, well before its current competitors. The company now is able to detect the risk of 26 different cancer types with high sensitivity and specificity.”
To view the full article, visit https://ibn.fm/izbZP
About AnPac Bio-Medical Science Co. Ltd.
AnPac Bio is a biotechnology company focused on early cancer screening and detection, with 142 issued patents as of March 31, 2021. With one CLIA- and CAP-registered clinical laboratory in the United States and two certified clinical laboratories in China, AnPac Bio performs a suite of cancer screening and detection tests, including CDA (Cancer Differentiation Analysis), biochemical, immunological and genomics tests. According to a Frost & Sullivan’s report issued in 2020, AnPac Bio ranked third worldwide among companies offering next-generation early cancer screening and detection technologies in terms of the number of clinical samples for cancer screening and detection in 2019. The company has a significant cancer screening and detection database consisting of approximately 43,900 clinical samples as of March 31, 2021. AnPac Bio’s CDA technology platform has been shown in retrospective validation studies to be able to detect the risk of over 20 different cancer types with high sensitivity and specificity. For more information, visit www.AnpacBio.com.
NOTE TO INVESTORS: The latest news and updates relating to ANPC are available in the company’s newsroom at https://ibn.fm/ANPC
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
